DEF 14A: KORU Medical Systems Announces 2024 Annual Meeting of Shareholders

KORU Medical Systems will hold its 2024 Annual Meeting of Shareholders on May 9, 2024, to vote on director elections, executive compensation, auditor ratification, and an equity incentive plan.

Summary

• KORU Medical Systems, Inc. is holding its Annual Meeting of Shareholders on May 9, 2024, at 8:00 a.m. Eastern Time at the company's offices in Mahwah, NJ.
• Shareholders of record as of March 11, 2024, are entitled to vote on several key proposals.
• The proposals include the election of seven directors, advisory approval of executive compensation, ratification of the appointment of McGrail Merkel Quinn & Associates, P.C. as independent registered public accountants, and approval of the 2024 Omnibus Equity Incentive Plan.
• The board of directors recommends voting FOR all director nominees and FOR proposals 2, 3, and 4.
• The company has adopted householding, which means that shareholders with the same address and last name will receive a single set of proxy materials unless they request individual copies.
• The board has determined that all non-employee directors are independent, except for Ms. Tharby and Mr. Wholihan.
• The company maintains a Code of Ethics applicable to all directors, officers, and employees.
• The board is actively engaged in overseeing the company's risk management.
• The company is committed to fostering a culture of diversity, equity, and inclusion.
• The company intends to establish an ESG working group to lead its ESG strategy.
• The company's non-employee director compensation includes a cash retainer of $50,000 and a common stock award of $60,000.
• The board is seeking shareholder approval for the 2024 Omnibus Equity Incentive Plan, which will replace the 2021 Equity Plan, the 2015 Stock Option Plan, and the Nonemployee Director Compensation Plan for future grants.
• The 2024 Equity Plan will provide for the issuance of up to 2,300,000 shares of common stock, plus any unissued shares reserved and available for issuance under the 2021 Equity Plan, 2015 Equity Plan and Non-Employee Director Compensation Plan (an aggregate 844,687 shares as of March 25, 2024).
• The audit committee has selected McGrail Merkel Quinn & Associates, P.C. as the company's independent auditors for fiscal year 2024.
• The company's largest shareholders include Joseph M. Manko, Jr. and Horton Capital Management, LLC, each beneficially owning 16.7% of the outstanding shares.
• First Light Asset Management, LLC beneficially owns 11.1% of the shares, and Archon Capital Management, LLC beneficially owns 8.0% of the shares.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposals being presented are typical for a public company, and the board's recommendations are clear. The company's commitment to corporate governance and social responsibility is a positive sign.

Positives

• The company has a Code of Ethics and an Ethics Hotline to address potential conflicts of interest.
• The board is actively engaged in overseeing the company's risk management.
• The company is committed to fostering a culture of diversity, equity, and inclusion.
• The company intends to establish an ESG working group to lead its ESG strategy.
• The board has determined that all non-employee directors are independent, except for Ms. Tharby and Mr. Wholihan.

Negatives

• One late Form 4 for Brian Case and a late Form 3 for Tom Adams were filed in fiscal year 2023.

Risks

• The company's performance targets may include various criteria, and the board has the discretion to amend these targets.
• The vote on executive compensation is advisory and non-binding.
• The company's financial results could be subject to restatement, potentially leading to clawback of incentive compensation.
• The company's ability to attract and retain qualified non-employee directors depends on providing competitive compensation.
• The company's success depends on the development, manufacturing, and commercialization of innovative subcutaneous drug delivery systems.

Future Outlook

The company intends to establish an ESG working group to be responsible for leading its ESG strategy and monitoring its corporate social responsibility and sustainability initiatives.

Industry Context

This announcement is typical for publicly traded companies as they prepare for their annual shareholder meetings, covering standard agenda items such as director elections, executive compensation, and auditor ratification. The inclusion of a vote on an equity incentive plan is common, as companies use these plans to attract and retain talent.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and stock awards, is consistent with industry practices for companies of similar size and stage.
• The topics covered in the proxy statement, such as director independence, committee structure, and risk oversight, align with corporate governance best practices.
• The proposed 2024 Omnibus Equity Incentive Plan is a common tool used by public companies to align the interests of employees and shareholders.
• The audit fee amounts are within a reasonable range for a company of KORU Medical's size and complexity.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key proposals that affect the company's governance and performance.
• Employees may be affected by the approval of the 2024 Omnibus Equity Incentive Plan.
• The company's commitment to corporate responsibility and sustainability may impact its relationships with customers and suppliers.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Shareholders on May 9, 2024.
• The company will report the final voting results on a Form 8-K filed with the SEC following the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Shareholders, Proxy Statement, Board of Directors, Executive Compensation, Equity Incentive Plan, Director Election, Corporate Governance, KORU Medical Systems